COMMUNIQUÉS West-GlobeNewswire

UCB - Convening Notice to the General Meeting of the Shareholders 2026
27/03/2026
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the general meeting of the shareholders (the “ General Meeting ”) which will be held on Thursday, 30 April 2026 [...]
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
27/03/2026
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate [...]
UCB - Convocation à l'assemblée générale des actionnaires 2026
27/03/2026
CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’administration invite les actionnaires à l’assemblée générale des actionnaires (« l’Assemblée Générale ») qui se tiendra le jeudi 30 avril 2026 à 11 [...]
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
27/03/2026
If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) , a rare primary immunodeficiency Decision based on [...]
MEDVi Claims Evaluated: Most Affordable Tirzepatide GLP-1 Weight Loss Clinic Online — 2026 Search Trends and Publicly Available Pricing Information Context
27/03/2026
A 2026 informational overview of publicly available MEDVi tirzepatide GLP-1 pricing details, compounded medication access pathways, program structure, and regulatory context relevant to consumers researching affordable [...]
Gelatine Sculpt Claims Evaluated: Documenting the Gelatin Trick Recipe Investigation for Consumer Safety
27/03/2026
A 2026 consumer transparency report addressing Gelatine Sculpt's "bariatric jelly" terminology, gelatin trick recipe marketing references, GLP-1-related positioning, ingredient disclosure, proprietary blend context, and [...]
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
27/03/2026
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the [...]
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
27/03/2026
Awiqli ® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli ® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these [...]
Radiant Health Centers Names Mark Gonzales Interim CEO Amid Period of Expansion
27/03/2026
Veteran Leader with 15+ Years of Service to Guide Growth, Increase Access to Care, and Deepen Community Impact Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers today announced the appointment of [...]
XORTX Announces Change of Effective Date of Share Consolidation
26/03/2026
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
26/03/2026
-- Zola ® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed business combination -- -- Exercise of preferred investment options yields $2.1 million gross proceeds -- DALLAS, [...]
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
26/03/2026
LOUISVILLE, Ky., March 26, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant [...]
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
26/03/2026
Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and physician demand Results [...]
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for [...]
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
26/03/2026
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phase 3, randomized, [...]
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
26/03/2026
Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq. Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System ( [...]
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
26/03/2026
Application supported by comprehensive clinical program, including two positive Phase 3 trials evaluating once-daily oral paltusotine in acromegaly SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals [...]
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
26/03/2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ [...]
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2025 le 31 mars 2026
26/03/2026
Conférence téléphonique et diffusion en direct sur Internet le mercredi 1er avril 2026 à 14h00 CEST / 8h00 EDT PARIS et CAMBRIDGE, Mass., 26 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – [...]

Pages